865 iosH2 exerts potent anti-tumor activity by blocking LILRB1/2 and KIR3DL1 receptor signaling

• Anil Kumar,
• Michael Curran,
• Christoph Renner,
• Osiris Marroquin Belaunzaran,
• Sean Smith,
• Anahita Rafiei,
• Marco Gualandi,
• Magdalena Westphal,
• Lorenz Vogt

Affiliations

Anil Kumar

1 General and Colorectal Surgery, Stockport NHS Foundation Trust, Stockport, UK

Michael Curran

Aff1 grid.240145.60000000122914776Department of ImmunologyUniversity of Texas MD Anderson Cancer Center Houston TX USA

Christoph Renner

Aff2 grid.410567.1Department of OncologyUniversity Hospital Basel Basel Switzerland

Osiris Marroquin Belaunzaran

Aff1 grid.412004.30000000404789977Department of OncologyUniversity Hospital Zurich Zurich Switzerland

Sean Smith

Silverback Therapeutics, Seattle, WA, USA

Anahita Rafiei

1ImmunOs Therapeutics AG, Schlieren, Switzerland

Marco Gualandi

1ImmunOs Therapeutics AG, Schlieren, Switzerland

Magdalena Westphal

1ImmunOs Therapeutics AG, Schlieren, Switzerland

Lorenz Vogt

1ImmunOs Therapeutics AG, Schlieren, Switzerland